Nomura Asset Management Co. Ltd. Buys 35,758 Shares of argenex SE $ARGX

Nomura Asset Management Co. Ltd. grew its stake in shares of argenex SE (NASDAQ:ARGX) by 262.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 49,358 shares of the company’s stock after purchasing an additional 35,758 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in argenex were worth $41,508,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of argenex by 91.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after acquiring an additional 4,217 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of argenex by 11.6% in the third quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after acquiring an additional 23,864 shares in the last quarter. Allianz Asset Management GmbH grew its holdings in shares of argenex by 21.3% in the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after acquiring an additional 645 shares in the last quarter. US Bancorp DE grew its holdings in shares of argenex by 37.2% in the third quarter. US Bancorp DE now owns 7,073 shares of the company’s stock valued at $5,217,000 after acquiring an additional 1,919 shares in the last quarter. Finally, Sands Capital Management LLC bought a new position in shares of argenex in the third quarter valued at approximately $12,262,000. 60.32% of the stock is owned by institutional investors.

argenex Price Performance

Shares of ARGX opened at $835.99 on Monday. The firm has a market cap of $51.99 billion, a PE ratio of 37.22, a PEG ratio of 1.32 and a beta of 0.47. The stock’s fifty day moving average price is $779.30 and its two-hundred day moving average price is $814.88. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The firm had revenue of $1.31 billion for the quarter. Sell-side analysts anticipate that argenex SE will post 25.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a report on Monday, March 9th. Oppenheimer reduced their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Finally, HC Wainwright upped their target price on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $1,017.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.